Global Advisory Board
Global Entrepreneur Stroke Survivor
Mr. Guglielmetti founded his first company at 19 and is one of the pioneers of the Internet in Europe. In 1999, at the age of 34, he IPO’d the unicorn Integra, an internet company founded three years earlier, and sold it two years later (with more than 1,100 employees) to Genuity, a subsidiary of Verizon. Integra was the leading company in Europe for managed and e-commerce web site hosting, with operations in the United Kingdom, Germany, France, Italy, Spain, The Netherlands, Norway, Sweden, Denmark and Iceland. Mr. Guglielmetti co-founded I-base, one of the first companies in Europe specialized in marketing databases and sold to Publicis in 2006 and incorporated Zeepro – a company designing and making 3D printers – in San Francisco in fall 2013.
On May 9, 2015 – at the age of 50 – Mr. Guglielmetti suffered a hemorrhagic pontine stroke. He survived and is since affected on both sides of the body because of the central location of the stroke (extremely rare). He recovered his independence for basic routines and considers himself very fortunate because the death rate for the type of stroke he had is close to 70% and most survivors remain in a severely disabled state.
Mr. Guglielmetti always enjoyed communicating and exchanging ideas and participated in numerous conferences, such as TedX. as an entrepreneur before the stroke.
He is living his rehabilitation as a new adventure.
CEO ResearchPoint Global - WuXi App Tec
Mr. Farinacci is the founder of ResearchPoint Global. He served as executive vice president of Quintiles Transnational Corporation, where he provided key leadership in acquisitions and integrations, helping Quintiles to become the CRO industry’s market leader. He also served as president and chief operating officer and held other senior executive positions at Pharmaco (currently PPD). During his tenure there, he played a pivotal role in moving Pharmaco to the second largest CRO in the industry. He also worked with Sterling Drug earlier on in his career. He received the PharmaVoice 100 most inspirational leaders award in the health and science industry in July 2009.
Linda Coleman, JD
Director of the Human Research Protection Program - Yale University
Prior to joining Yale in April 2016, Ms. Coleman held several positions at Quorum Review, an independent IRB and consulting company that serves institutional, independent, and international sites. From January 2016 until March 2016, Ms. Coleman served as Quorum’s vice president of regulatory and legal affairs of Kinetiq, a division of Quorum. Prior to 2016, she served as Quorum’s director of regulatory affairs and general counsel from 2011 until 2015, and its director of regulatory affairs from 2007 until 2010.
From 2011 to the present, Ms. Coleman has been a member of the Industry Pharmacogenomics Education Task Force, a subcommittee of the Industry Pharmacogenomics Working Group (I-PWG). Ms. Coleman is also the team lead for the Mobile Clinical Trials working group of the Clinical Trials Transformation Initiative, and actively participates on other committees related to research, health law, and education.
Ms. Coleman was an attorney at Bennett, Bigelow & Leedom where her practice focused on regulatory compliance, Medicare and Medicaid reimbursement, healthcare litigation, business/transactional, behavioral health, employment law and general patient care delivery matters. In addition to her law degree, Ms. Coleman holds the following certifications: CHC (Certified in Healthcare Compliance), CHRC (Certified in Healthcare Research Compliance), CCEP-I (Certified Compliance & Ethics Professional – International), and CIP (Certified IRB Professional).
“Collaboration is essential in order to solve the complex problems that face our healthcare and research industry. BlueCloud has created the perfect collaborative mechanism to help modernize the healthcare and research industry because it provides solutions regarding issues and shared interests that cannot be addressed by any single individual or organization. Stakeholders with a shared interest and vision must therefore work together to develop solutions to the problems that plague our industry.”
Sophia Ononye-Onyia, PhD, MPH, MBA
Founder & CEO - The Sophia Consulting Firm
Dr. Sophia Nnenna Ononye-Onyia is a Nigerian-American entrepreneur and life science strategist with interests in and passion for oncology, innovative drug development, digital health and value-based care. She recently founded The Sophia Consulting Firm where she leads the provision of fully integrated communication services for clients in the biotechnology, pharmaceutical, healthcare technology and consumer space. A former Pfizer scientist and Yale-trained molecular oncologist, Sophia utilizes her multidisciplinary background (PhD, MPH, MBA) to advise clients in the life science industry on value communications and strategy planning for new drug launches with a specialty focus on oncology.
Chairman - Cardiff Ocean Group & Chief Digital Officer - Scripps Translational Science Institute
Mr. Jones advises companies, healthcare providers, governments and foundations on digital heath, the Internet of Medical Things and technology-enabled services. He is globally recognized for his expertise in wireless technologies, mobility and network effect for fitness, health and healthcare products, apps, services and therapies. He sits on multiple boards and has spent more than 30 years developing, founding and growing mobile healthcare enterprises. In the early 1980s, he developed the $3B critical care transportation sector. During the mid-80s and into the 90s, he won billions of dollars of multi-year EMS contracts throughout the US. In the mid 1990s, he developed AMR’s healthcare call center strategy, American Medical Pathways.
Jones is a founding advisor of Golden Hour Data Systems, an information technology and revenue cycle management company, managing more than $2B in aero-medical revenue. In 1998, the Director of the US National Highway and Transportation Safety Administration asked Jones to co-author the Federal Government’s EMS Implementation Guide for the Future. In 2000, the Journal of Emergency Medical Services named Jones ‘One of the 20 Most Influential People in EMS’.
“BlueCloud provides the industry with private, secure communication networks and is key to driving network effect in health care and life science by reducing friction and producing economic efficiencies by using data rich directories and facilitating information sharing and coordination of workflows.”
Global Head Clinical Operations - Agenus Biotechnology
Mr. Moreira has more 25 years of experience in clinical research and industry consulting. He has a long tenure of 15 years at EMD Serono over Clinical Operations, as Global Head of Clinical Strategic Partnering, as VP of Clinical External Innovation and is currently with Agenus Biotechnology. Mr. Moreira is also a Visiting Scholar at Boston College where he teaches at the Pathways in Clinical Research Program. He is very active in several industry-wide organizations and also serves on the Steering Committee of the Clinical Trial Transformation Initiative.
Mr. Moreira is a Timpanio-auditorial and hearing patient.
Jeff Kasher, PhD
President, Founder - Patients Can't Wait
Dr. Kasher is passionate about improving outcomes, bringing patient and research sites into the development process and dramatically decreasing the time to market for promising drug candidates. He is known as a pharmaceutical development change catalyst with 28 years of leadership experience at Eli Lilly, where most recently he managed a portfolio of innovative clinical development approaches to achieve 50% cost and time reductions over a five-year period beginning in 2017.
Dr. Kasher continues to advocate for innovation within clinical trials, as president of Patients Can’t Wait. Dr. Kasher was a founding member of TransCelerate Biopharma Operations Committee and the Avoca Quality Consortium. He sits on the DPharm Europe steering committee and faculty, is a member of Linking Leaders and is chairman of the DrugDev Advisory Board. In 2013, CenterWatch named Dr. Kasher one of “20 Innovators Changing the Face of the Clinical Trials Industry.” Dr. Kasher received a bachelor’s. in chemistry from Franklin & Marshall College, a doctorate in pharmacology from the State University of New York, and a post-doctoral fellowship in physiology at Yale University School of Medicine.
He is a heart and cardiovascular patient survivor.
“BlueClouds are easy to use/readily configurable systems which empower an individual, group, or organization to collect, clean and share verified data/information through verified connections with an individual, group or organization around the world in real time.”
Amir Kalali, MD
Founder, Chief Curator & Chairman - CNS Summit
Dr. Kalali is the Founder of CNS Summit. He previously served as vice president of Medical and Scientific Services and as Global Therapeutic Team Leader CNS of Quintiles Inc. Dr. Kalali is globally responsible for the medical and scientific aspects of development programs in psychiatry and neurology. He is also a professor of psychiatry at the University of California, San Diego. He also served as a clinical research faculty of the University of California, Irvine, where he held several positions. His focus is in accelerating development of new treatments through the principles of collaboration, innovation and emerging technologies.
Managing Director and Co-Founder - Lumis International GmbH
Ms. Schoen is Senior Manager for Lumis International GmbH with more than 25 years of experience in leadership positions in international clinical research and drug development. She has profound knowledge of the clinical drug development processes and regulatory requirements from first-in-human to market access. Ms. Schoen develops strategies and concepts for biopharmaceutical and medical device companies covering clinical operations, clinical research, outsourcing, vendor management and oversight management. She as experience working in small, midsized and global companies within the CRO, consulting and biotech industry. Her expertise covers a broad spectrum of indications with a focus on oncology, CNS, HIV and medical devices and is regularly invited as a speaker regarding outsourcing, oversight management. Ms. Schoen was president of the Global Board of Trustees of ACRP from 2009 until 2011.
Ms. Schoen’s specialties include optimizing and/or creating efficient processes and structures, solution-oriented problem solving, clinical trials in numerous indications, project management, cross-cultural training, coaching and mentoring.
Jamie Skipper, RN, PhD,
Healthcare Policy Advisor and Strategist CEO - Elevation Health Consulting
Dr. Skipper is a nationally respected expert on setting policies and standards for health data infrastructures. She is currently the CEO of Elevation Health Consulting. Here, Dr. Skipper advises public and private stakeholders across the healthcare arena on how to strategically improve health outcomes with a person-centric motto through leveraging, improving or building health technology. Dr. Skipper is also the Chief Scientist at EMI Advisors, providing expertise to federal agencies and partners on building data infrastructure to support research.
Cancer Blogger, Survivor & Advocate
Mr. Sharpe is a Stage IV melanoma patient who shares his journey through cancer in the Patient #1 Blog found on http://www.philly.com/patient1/, www.SkinCancer.net, www.oncology-central.com, and www.NovartisOncology.com. He was diagnosed in August 2012 with melanoma tumors in multiple organs, only four weeks after his second child was born. Since then, he has undergone six surgeries and four immunotherapy treatments over two different clinical trials. In addition to writing, he is a keynote speaker and consultant to the biopharma and clinical research industries, bringing an educated patient voice as a true stakeholder in challenging healthcare’s status and making a difference in patients’ lives via his company, Starfish Harbor LLC.
Greg Koski, MD, PhD
Co-Founder, President, CEO - Alliance for Clinical Research Excellence & Safety (ACRES)
Dr. Koski is an internationally recognized leader in clinical research championing a systemic approach to transforming the infrastructure and ecosystem for conducting clinical research globally; and a “culture of conscience” in human research, focusing on prevention of harm and quality improvement beyond regulatory compliance. Dr. Koski has been influential in enhancing research processes internationally, including processes for accreditation of research sites and human research protections programs, certification of physician investigators, and the formation of an industry organization for contract research organizations.
“The BlueCloud network provides a shared universal interface to connect and support collaboration and inter-operability at a critical moment in the system transformation underway in healthcare and research — it is a catalyst for change, both in technology and culture — its potential impact cannot be overstated.”
Manager, Study Start Up & Patient Recruitment - Bayer Pharmaceuticals
Mr. Bilkic has worked as an associate project manager at AstraZeneca and a scientist at GlaxoSmithKline Inc. He has more than 20 years of experience in the pharmaceutical industry where he has held various positions from working in research on the lab bench to managing clinical trials. He is an accomplished leader in the pharmaceutical industry with progressive and extensive experience in contractual negotiations, vendor selection/management and budget planning. Using his capabilities in providing strategic direction, managing diverse functional groups and eliciting peak team performance and leadership, Mr. Bilkic currently works with TransCelerate Biopharma Inc., working to enhance clinical research efficiency.
“In clinical research it is paramount that we stay connected and organized. BlueCloud enhances our ability to share information and communicate as professionals as we strive to develop new medicines. Our industry is in great need of improvement to efficiencies and the BlueCloud Networking system is an effective way of getting us there. This greatly benefits all the stakeholders and is of special importance for the health and welfare of our patients.”